For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Kura Oncology, Inc.

USPTO Granted Patents = 33

EPO Patents = 11

Trademarks = 4

Forward Citations = 86

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Pingda Ren (17 out of 136 patents)

Liansheng Li (15 out of 114 patents)

Tao Wu (15 out of 89 patents)

4. Antonio Gualberto (13 out of 17 patents)

5. Catherine Rose Scholz (11 out of 16 patents)

6. Yi Liu (10 out of 149 patents)

7. Tomasz Cierpicki (10 out of 28 patents)

8. Jolanta Grembecka (10 out of 31 patents)

9. Jonathan Pollock (10 out of 10 patents)

10. Dmitry Borkin (10 out of 16 patents)

11. Jun Feng (9 out of 84 patents)

12. Szymon Klossowski (6 out of 13 patents)

13. Yi Wang (5 out of 40 patents)

14. Hongzhi Miao (2 out of 8 patents)

15. Duxin Sun (2 out of 26 patents)

33 patents: Sort by Forward Citations

1. 12466835 - Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same (2025-11-11),

2. 12410184 - Crystalline forms of a menin inhibitor (2025-09-09),

3. 12018011 - Macrocyclic compounds and compositions, and methods of preparing and using the same (2024-06-25),

4. 11944627 - Methods for treating hematological malignancies and Ewing's sarcoma (2024-04-02),

5. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

6. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

7. 11672774 - Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors (2023-06-13),

8. 11649251 - Substituted inhibitors of menin-MLL and methods of use (2023-05-16),

9. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

10. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

11. 11542244 - Synthesis of tipifarnib (2023-01-03),

12. 11541045 - Methods of treating cancer with farnesyltransferase inhibitors (2023-01-03),

13. 11291663 - Methods of treating cancer with farnesyltransferase inhibitors (2022-04-05),

14. 11207314 - Methods of treating cancer patients with farnesyltransferase inhibitors (2021-12-28),

15. 11124839 - Methods of treating cancer patients with farnesyltransferase inhibitors (2021-09-21),

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their mission is to transform cancer therapy through the development of innovative small molecule drugs that target hard-to-treat cancers. With a strong pipeline of potential therapies, Kura Oncology is committed to improving outcomes for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

33 Patents

#183 in San Diego, CA

#2,380 in California

#9,941 in US

#19,537 in the World

San Diego, CA, United States of America

Kura Oncology, Inc.

Forward Citations = 86

38 inventors:

Pingda Ren (17 out of 136 patents)

Liansheng Li (15 out of 114 patents)

Tao Wu (15 out of 89 patents)

4. Antonio Gualberto (13 out of 17 patents)

5. Catherine Rose Scholz (11 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…